Tennessee House of Representatives bill in Session 114.
Status: enacted. Latest action: April 24, 2026.
AN ACT to amend Tennessee Code Annotated, Title 53, Chapter 11, relative to the use of buprenorphine products.
Present law allows a prescription for buprenorphine mono or buprenorphine without the use of naloxone for the treatment of substance use disorder to be prescribed only for certain, explicitly listed patients, including a patient who is directly administe red buprenorphine mono or buprenorphine without the use of naloxone by a licensed physician or osteopathic physician. This bill adds to the list a patient who is directly administered buprenorphine mono or buprenorphine without the use of naloxone by oth er healthcare providers who are permitted to prescribe Schedule II or III drugs if they meet the conditions for prescribing buprenorphine products as provided in present law. Present law prohibits healthcare providers that are not licensed physicians or osteopathic physicians from prescribing a mono or buprenorphine product without naloxone, except to a pregnant woman or to a patient with a documented history of an adverse re action to naloxone. This bill authorizes such drugs to also be dispensed without naloxone to nursing mothers or if the prescription is for an injectable mono product.
| Date | Event | Detail |
|---|---|---|
| 2026-01-21 | Introduced | Bill introduced |
| 2026-04-24 | Status | enacted |
| 2026-04-24 | Latest Action | Comp. became Pub. Ch. 753 |